trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 't-dxd', 'destiny,crc,02']
destiny-crc02 activity of t-dxd in advanced line #crc presented by #asco23. her2 targeting can't be delayed to late lines. patients can't wait for #ebm
Director of clinical research, #oncology
The opinions are my personal ones.